News
SONN
2.890
-1.03%
-0.030
Weekly Report: what happened at SONN last week (1111-1115)?
Weekly Report · 3d ago
Warning: SONN is at high risk of performing badly
Seeking Alpha · 11/13 13:35
Sonnet BioTherapeutics releases ‘What this Means’ segment
TipRanks · 11/12 14:31
Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment
Barchart · 11/12 08:15
Weekly Report: what happened at SONN last week (1104-1108)?
Weekly Report · 11/11 12:28
Sonnet BioTherapeutics prices $5M at-the-market offering
TipRanks · 11/06 18:25
SONNET BIOTHERAPEUTICS HOLDINGS INC - COMBINED OFFERING PRICE OF $4.50 PER SHARE AND WARRANT
Reuters · 11/06 18:20
Gold Down Over 2%; CVS Health Shares Jump After Q3 Results
Benzinga · 11/06 17:47
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 11/06 16:34
BUZZ-U.S. STOCKS ON THE MOVE-Revolve Group, US hospital operators, US airlines
Reuters · 11/06 16:01
Dow Jumps Over 1,200 Points; Donald Trump Wins White House
Benzinga · 11/06 15:26
Sonnet BioTherapeutics Secures Patent for Cancer Drugs
TipRanks · 11/06 14:20
Sonnet BioTherapeutics announces USPTO issued U.S. patent on IL-18
TipRanks · 11/06 13:41
Sonnet BioTherapeutics Announces Issuance Of U.S. Patent Covering A Variant IL-18 Incorporated Into Two Novel Immunotherapeutic Drug Candidates; Both Novel Bifunctional And Monofunctional Fusion Proteins Exhibit Wild-Type Binding To The IL-18 Receptor, Coupled With Undetectable Binding To The Inhibitory IL-18 Binding Protein
Benzinga · 11/06 13:33
SONNET BIOTHERAPEUTICS HOLDINGS INC - PATENT TERM EFFECTIVE UNTIL JUNE 2044
Reuters · 11/06 13:30
Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules
Barchart · 11/06 12:20
Weekly Report: what happened at SONN last week (1028-1101)?
Weekly Report · 11/04 12:23
Sonnet stock tumbles 22% in wake of proposed offering filing
Seeking Alpha · 10/28 16:45
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 10/28 16:30
BUZZ-U.S. STOCKS ON THE MOVE-Monte Rosa, EyePoint Pharma, Shake Shack
Reuters · 10/28 16:28
More
Webull provides a variety of real-time SONN stock news. You can receive the latest news about Sonnet Biotherapeutc Hldng Inc through multiple platforms. This information may help you make smarter investment decisions.
About SONN
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. Its technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. It designed the FHAB construct to improve drug accumulation in tumors, and to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12, covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical stage asset, SON-080, is the native human version of IL-6 that is manufactured in Chinese Hamster Ovary cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy and Diabetic Peripheral Neuropathy. Its pipeline also includes SON-1210, SON-1410 and SON-3015.